In addition, it is tempting to speculate whether additional criteria, such as tumor subtype, tumor stage or molecular features of the stroma, e.g., pSTAT3high in CAFs or CMS type IV (which both correlate with poor prognosis), might aid in enhancing precision and success in therapeutic approaches targeting STAT3 activation in CRC [9,11,27]. This evidence concerns the gene STAT3 and neoplasm.